{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T20:09:44Z","timestamp":1789934984036,"version":"4.0.1"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["UKRI430"],"award-info":[{"award-number":["UKRI430"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/Y007212\/1 527"],"award-info":[{"award-number":["BB\/Y007212\/1 527"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.imlet.2026.107235","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:33:54Z","timestamp":1787614434000},"page":"107235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Killing to cure: harnessing poxvirus-driven cell death for viral immunotherapy"],"prefix":"10.1016","volume":"283","author":[{"given":"April","family":"D\u2019Arcy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6873-1032","authenticated-orcid":false,"given":"Brian J.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0001","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12943-026-02651-4","article-title":"Bridging mechanism and clinic: unlocking the full potential of oncolytic virus-based immunotherapy","volume":"25","author":"Hua","year":"2026","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.imlet.2026.107235_bib0002","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.imlet.2026.107235_bib0003","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic viruses and the Immune system: the dynamic duo","volume":"17","author":"Lemos de Matos","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"7","key":"10.1016\/j.imlet.2026.107235_bib0004","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","article-title":"Oncolytic viruses as engineering platforms for combination immunotherapy","volume":"18","author":"Twumasi-Boateng","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.imlet.2026.107235_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953410","article-title":"Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements","volume":"13","author":"Yun","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imlet.2026.107235_bib0006","series-title":"FDA Grants Accelerated Approval to Vusolimogene Oderparepvec-Wtpg in Combination With Nivolumab For Melanoma","year":"2026"},{"key":"10.1016\/j.imlet.2026.107235_bib0007","series-title":"Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials","year":"2026"},{"issue":"3","key":"10.1016\/j.imlet.2026.107235_bib0008","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrmicro1099","article-title":"Poxvirus tropism","volume":"3","author":"McFadden","year":"2005","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.imlet.2026.107235_bib0009","series-title":"Smallpox and Its Eradication","author":"Fenner","year":"1988"},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0378-1119(83)90163-4","article-title":"Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA","volume":"25","author":"Smith","year":"1983","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.imlet.2026.107235_bib0011","first-page":"248","article-title":"PHOCUS: a phase 3, randomized, open-label study of sequential treatment with Pexa-Vec (JX-594) and Sorafenib in patients with advanced hepatocellular carcinoma","volume":"13","author":"Abou-Alfa","year":"2023","journal-title":"Liver. Cancer"},{"issue":"20","key":"10.1016\/j.imlet.2026.107235_bib0012","doi-asserted-by":"crossref","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-07-0146","article-title":"Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus","volume":"67","author":"Zhang","year":"2007","journal-title":"Cancer Res."},{"issue":"25","key":"10.1016\/j.imlet.2026.107235_bib0013","doi-asserted-by":"crossref","first-page":"40533","DOI":"10.18632\/oncotarget.17125","article-title":"Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9","volume":"8","author":"Deng","year":"2017","journal-title":"Oncotarget"},{"issue":"20","key":"10.1016\/j.imlet.2026.107235_bib0014","doi-asserted-by":"crossref","first-page":"10079","DOI":"10.1128\/JVI.00816-08","article-title":"Vaccinia virus WR53.5\/F14.5 protein is a new component of intracellular mature virus and is important for calcium-independent cell adhesion and vaccinia virus virulence in mice","volume":"82","author":"Izmailyan","year":"2008","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.imlet.2026.107235_bib0015","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00438-009-0475-1","article-title":"The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation","volume":"282","author":"Zhang","year":"2009","journal-title":"Mol Genet Genom."},{"issue":"7","key":"10.1016\/j.imlet.2026.107235_bib0016","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamaoncol.2023.1007","article-title":"Clinical activity of Olvimulogene Nanivacirepvec-primed immunochemotherapy in heavily pretreated patients with platinum-resistant or platinum-refractory ovarian cancer: the nonrandomized phase 2 VIRO-15 Clinical trial","volume":"9","author":"Holloway","year":"2023","journal-title":"JAMa Oncol."},{"key":"10.1016\/j.imlet.2026.107235_bib0017","series-title":"Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum-Resistant\/Refractory Ovarian Cancer","author":"Corporation","year":"2023"},{"issue":"3","key":"10.1016\/j.imlet.2026.107235_bib0018","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0019","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1186\/s12885-015-1753-4","article-title":"Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma","volume":"15","author":"Kung","year":"2015","journal-title":"BMC. Cancer"},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0042-6822(90)90294-2","article-title":"The complete DNA sequence of vaccinia virus","volume":"179","author":"Goebel","year":"1990","journal-title":"Virology"},{"issue":"13","key":"10.1016\/j.imlet.2026.107235_bib0021","doi-asserted-by":"crossref","first-page":"7590","DOI":"10.1128\/JVI.77.13.7590-7600.2003","article-title":"Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome","volume":"77","author":"Upton","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.imlet.2026.107235_bib0022","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.63332","article-title":"Poxviruses capture host genes by LINE-1 retrotransposition","volume":"11","author":"Fixsen","year":"2022","journal-title":"Elife"},{"issue":"Pt 11","key":"10.1016\/j.imlet.2026.107235_bib0023","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1099\/vir.0.055921-0","article-title":"Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity","volume":"94","author":"Smith","year":"2013","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.imlet.2026.107235_bib0024","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.imlet.2017.03.015","article-title":"Vaccinia virus evasion of regulated cell death","volume":"186","author":"Veyer","year":"2017","journal-title":"Immunol. Lett."},{"issue":"2","key":"10.1016\/j.imlet.2026.107235_bib0025","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.virusres.2004.08.015","article-title":"The exit of vaccinia virus from infected cells","volume":"106","author":"Smith","year":"2004","journal-title":"Virus. Res."},{"issue":"5","key":"10.1016\/j.imlet.2026.107235_bib0026","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0027","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.imlet.2026.107235_bib0028","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death. Differ."},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0029","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1152\/physrev.00002.2021","article-title":"The evolution of regulated cell death pathways in animals and their evasion by pathogens","volume":"102","author":"Tummers","year":"2022","journal-title":"Physiol. Rev."},{"issue":"5","key":"10.1016\/j.imlet.2026.107235_bib0030","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s41423-020-00630-3","article-title":"Necroptosis, pyroptosis and apoptosis: an intricate game of cell death","volume":"18","author":"Bertheloot","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"3","key":"10.1016\/j.imlet.2026.107235_bib0031","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/febs.14186","article-title":"Bax, Bak and beyond - mitochondrial performance in apoptosis","volume":"285","author":"Pe\u00f1a-Blanco","year":"2018","journal-title":"Febs. J."},{"issue":"5","key":"10.1016\/j.imlet.2026.107235_bib0032","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41422-019-0164-5","article-title":"The molecular machinery of regulated cell death","volume":"29","author":"Tang","year":"2019","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0033","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molcel.2019.02.013","article-title":"Apoptotic caspases suppress type I interferon production via the cleavage of cGAS, MAVS, and IRF3","volume":"74","author":"Ning","year":"2019","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0034","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.immuni.2008.05.013","article-title":"Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein","volume":"29","author":"Kazama","year":"2008","journal-title":"Immunity"},{"issue":"6258","key":"10.1016\/j.imlet.2026.107235_bib0035","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1126\/science.aad0395","article-title":"RIPK1 and NF-\u03baB signaling in dying cells determines cross-priming of CD8\u207a T cells","volume":"350","author":"Yatim","year":"2015","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.imlet.2026.107235_bib0036","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/cdd.2017.65","article-title":"Initiation and execution mechanisms of necroptosis: an overview","volume":"24","author":"Grootjans","year":"2017","journal-title":"Cell Death. Differ."},{"issue":"2","key":"10.1016\/j.imlet.2026.107235_bib0037","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.celrep.2016.03.037","article-title":"Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity","volume":"15","author":"Aaes","year":"2016","journal-title":"Cell Rep."},{"issue":"36","key":"10.1016\/j.imlet.2026.107235_bib0038","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw2004","article-title":"Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity","volume":"4","author":"Snyder","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.imlet.2026.107235_bib0039","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1146\/annurev-immunol-112019-072301","article-title":"The antisocial network: cross talk between cell death programs in host defense","volume":"39","author":"Snyder","year":"2021","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.imlet.2026.107235_bib0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-025-09536-4","article-title":"STING induces ZBP1-mediated necroptosis independently of TNFR1 and FADD","author":"Kelepouras","year":"2025","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.imlet.2026.107235_bib0041","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.chom.2021.05.009","article-title":"Vaccinia virus E3 prevents sensing of Z-RNA to block ZBP1-dependent necroptosis","volume":"29","author":"Koehler","year":"2021","journal-title":"Cell Host. Microbe"},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108760","article-title":"DNA-PKcs is required for cGAS\/STING-dependent viral DNA sensing in human cells","volume":"27","author":"Hristova","year":"2024","journal-title":"iScience"},{"issue":"7575","key":"10.1016\/j.imlet.2026.107235_bib0043","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nature15514","article-title":"Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death","volume":"526","author":"Shi","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0044","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-021-00507-5","article-title":"Pyroptosis: mechanisms and diseases","volume":"6","author":"Yu","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"7848","key":"10.1016\/j.imlet.2026.107235_bib0045","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41586-021-03218-7","article-title":"NINJ1 mediates plasma membrane rupture during lytic cell death","volume":"591","author":"Kayagaki","year":"2021","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.imlet.2026.107235_bib0046","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/cr.2015.139","article-title":"Gasdermin D is an executor of pyroptosis and required for interleukin-1\u03b2 secretion","volume":"25","author":"He","year":"2015","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0047","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/s41467-019-09397-2","article-title":"Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation","volume":"10","author":"Rogers","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.imlet.2026.107235_bib0048","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14128","article-title":"Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic\/pyroptotic cell death","volume":"8","author":"Rogers","year":"2017","journal-title":"Nat. Commun."},{"issue":"7661","key":"10.1016\/j.imlet.2026.107235_bib0049","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature22393","article-title":"Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin","volume":"547","author":"Wang","year":"2017","journal-title":"Nature"},{"issue":"7799","key":"10.1016\/j.imlet.2026.107235_bib0050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41586-020-2071-9","article-title":"Gasdermin E suppresses tumour growth by activating anti-tumour immunity","volume":"579","author":"Zhang","year":"2020","journal-title":"Nature"},{"issue":"7799","key":"10.1016\/j.imlet.2026.107235_bib0051","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-020-2079-1","article-title":"A bioorthogonal system reveals antitumour immune function of pyroptosis","volume":"579","author":"Wang","year":"2020","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.imlet.2026.107235_bib0052","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.imlet.2026.107235_bib0053","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41580-024-00703-5","article-title":"The cell biology of ferroptosis","volume":"25","author":"Dixon","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.imlet.2026.107235_bib0054","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"7","key":"10.1016\/j.imlet.2026.107235_bib0055","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41419-023-05930-w","article-title":"Ferroptosis as a potential target for cancer therapy","volume":"14","author":"Chen","year":"2023","journal-title":"Cell Death. Dis."},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0056","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12985-023-02122-y","article-title":"Vaccinia virus induces endoplasmic reticulum stress and activates unfolded protein responses through the ATF6\u03b1 transcription factor","volume":"20","author":"Le\u00e3o","year":"2023","journal-title":"Virol. J."},{"issue":"5","key":"10.1016\/j.imlet.2026.107235_bib0057","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4049\/jimmunol.1900216","article-title":"ZBP1\/DAI Drives RIPK3-mediated cell death induced by IFNs in the absence of RIPK1","volume":"203","author":"Ingram","year":"2019","journal-title":"J. Immunol."},{"issue":"14","key":"10.1016\/j.imlet.2026.107235_bib0058","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1111\/febs.13598","article-title":"Cell death induced by endoplasmic reticulum stress","volume":"283","author":"Iurlaro","year":"2016","journal-title":"Febs. J."},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0059","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10010006","article-title":"Poxviral strategies to overcome host cell apoptosis","volume":"10","author":"Suraweera","year":"2020","journal-title":"Pathogens"},{"issue":"Pt 12","key":"10.1016\/j.imlet.2026.107235_bib0060","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1099\/vir.0.068833-0","article-title":"Analysis of the anti-apoptotic activity of four vaccinia virus proteins demonstrates that B13 is the most potent inhibitor in isolation and during viral infection","volume":"95","author":"Veyer","year":"2014","journal-title":"J. Gen. Virol."},{"issue":"49","key":"10.1016\/j.imlet.2026.107235_bib0061","doi-asserted-by":"crossref","first-page":"81208","DOI":"10.18632\/oncotarget.12820","article-title":"Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis","volume":"7","author":"Wilkinson","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0062","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41419-020-2236-3","article-title":"Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer","volume":"11","author":"Ma","year":"2020","journal-title":"Cell Death. Dis."},{"issue":"11","key":"10.1016\/j.imlet.2026.107235_bib0063","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/mt.2013.195","article-title":"Vaccinia virus induces programmed necrosis in ovarian cancer cells","volume":"21","author":"Whilding","year":"2013","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.imlet.2026.107235_bib0064","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.cell.2009.05.037","article-title":"Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation","volume":"137","author":"Cho","year":"2009","journal-title":"Cell"},{"issue":"Pt 4","key":"10.1016\/j.imlet.2026.107235_bib0065","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1099\/0022-1317-80-4-949","article-title":"Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors","volume":"80","author":"Alcam","year":"1999","journal-title":"J. Gen. Virol."},{"issue":"2","key":"10.1016\/j.imlet.2026.107235_bib0066","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.immuni.2020.11.020","article-title":"A class of viral inducer of degradation of the necroptosis adaptor RIPK3 regulates virus-induced inflammation","volume":"54","author":"Liu","year":"2021","journal-title":"Immunity"},{"issue":"13","key":"10.1016\/j.imlet.2026.107235_bib0067","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1016\/j.celrep.2019.08.055","article-title":"Viral MLKL homologs subvert necroptotic cell death by sequestering cellular RIPK3","volume":"28","author":"Petrie","year":"2019","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.imlet.2026.107235_bib0068","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/ni.1864","article-title":"The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses","volume":"11","author":"Rathinam","year":"2010","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0069","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41467-023-35917-2","article-title":"Oncolytic parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity","volume":"14","author":"Lin","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0070","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12985-025-02672-3","article-title":"Development of attenuated Orf virus as a safe oncolytic viral vector for nasopharyngeal carcinoma treatment","volume":"22","author":"Yamada","year":"2025","journal-title":"Virol. J."},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0071","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2025.2522877","article-title":"Monkeypox virus induces ferroptosis to facilitate viral replication and promotes inflammatory responses","volume":"14","author":"Chuai","year":"2025","journal-title":"Emerg. Microbes. Infect."},{"issue":"6","key":"10.1016\/j.imlet.2026.107235_bib0072","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10061425","article-title":"Ferroptosis inducer improves the efficacy of oncolytic virus-mediated cancer immunotherapy","volume":"10","author":"Liu","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.imlet.2026.107235_bib0073","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.omto.2019.06.004","article-title":"Deletion of apoptosis inhibitor F1L in Vaccinia virus increases safety and oncolysis for cancer therapy","volume":"14","author":"Pelin","year":"2019","journal-title":"Mol. Ther. Oncolytics."},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0074","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1802968","article-title":"Recombinant viruses delivering the necroptosis mediator MLKL induce a potent antitumor immunity in mice","volume":"9","author":"Van Hoecke","year":"2020","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.imlet.2026.107235_bib0075","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s13577-014-0093-z","article-title":"SMAC-armed vaccinia virus induces both apoptosis and necroptosis and synergizes the efficiency of vinblastine in HCC","volume":"27","author":"Pan","year":"2014","journal-title":"Hum. Cell"},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0076","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12985-022-01779-1","article-title":"Oncolytic therapy with vaccinia virus carrying IL-24 for hepatocellular carcinoma","volume":"19","author":"Deng","year":"2022","journal-title":"Virol. J."},{"issue":"5","key":"10.1016\/j.imlet.2026.107235_bib0077","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1134\/S0026893313050075","article-title":"Apoptin enhances the oncolytic activity of vaccinia virus in vitro","volume":"47","author":"Kochneva","year":"2013","journal-title":"Mol. Biol."},{"key":"10.1016\/j.imlet.2026.107235_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvr.2025.200333","article-title":"Oncolytic virus and immunogenic cell death in cancer therapy","volume":"20","author":"Cao","year":"2025","journal-title":"Tumour Virus Res."},{"issue":"5","key":"10.1016\/j.imlet.2026.107235_bib0079","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world's first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"issue":"12","key":"10.1016\/j.imlet.2026.107235_bib0080","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1586\/14737140.2015.1115725","article-title":"Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy","volume":"15","author":"Harrington","year":"2015","journal-title":"Expert. Rev. AntiCancer Ther."},{"issue":"8","key":"10.1016\/j.imlet.2026.107235_bib0081","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/oncolo\/oyad041","article-title":"Regulatory issues: PMDA - review of Sakigake Designation products: oncolytic virus therapy with delytact injection (Teserpaturev) for malignant glioma","volume":"28","author":"Maruyama","year":"2023","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.imlet.2026.107235_bib0082","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3233\/BLC-230083","article-title":"The evolution of Nadofaragene Firadenovec: a review and the path forward","volume":"10","author":"Steinmetz","year":"2024","journal-title":"Bladder. Cancer"},{"issue":"10","key":"10.1016\/j.imlet.2026.107235_bib0083","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.tim.2008.07.009","article-title":"Vaccinia virus morphogenesis and dissemination","volume":"16","author":"Roberts","year":"2008","journal-title":"Trends. Microbiol."},{"issue":"2","key":"10.1016\/j.imlet.2026.107235_bib0084","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ymthe.2004.10.015","article-title":"Fighting cancer with vaccinia virus: teaching new tricks to an old dog","volume":"11","author":"Shen","year":"2005","journal-title":"Mol. Ther."},{"issue":"22","key":"10.1016\/j.imlet.2026.107235_bib0085","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-10-2082","article-title":"Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study","volume":"16","author":"Amato","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.imlet.2026.107235_bib0086","unstructured":"Transgene, Transgene reports on the combination trial of TG4010, chemotherapy and nivolumab in non-small cell lung cancer, Transgene, 2019. https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/12\/20191212-PR-TG4010_EN_results.pdf."},{"key":"10.1016\/j.imlet.2026.107235_bib0087","series-title":"Transgene Provides Update On Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers","year":"2024"},{"issue":"3","key":"10.1016\/j.imlet.2026.107235_bib0088","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00262-022-03274-6","article-title":"Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma","volume":"72","author":"Sonpavde","year":"2023","journal-title":"Cancer Immunol. Immunther."},{"issue":"4","key":"10.1016\/j.imlet.2026.107235_bib0089","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01495-21","article-title":"Ancient gene capture and recent gene loss shape the evolution of orthopoxvirus-host interaction genes","volume":"12","author":"Senkevich","year":"2021","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0090","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0092-8674(92)90274-G","article-title":"A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection","volume":"71","author":"Alcam\u00ed","year":"1992","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.imlet.2026.107235_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112878","article-title":"Structural homology screens reveal host-derived poxvirus protein families impacting inflammasome activity","volume":"42","author":"Boys","year":"2023","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.imlet.2026.107235_bib0092","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03809-24","article-title":"Temporal expression classes and functions of vaccinia virus and mpox (monkeypox) virus genes","volume":"16","author":"Deng","year":"2025","journal-title":"MBio"},{"issue":"1","key":"10.1016\/j.imlet.2026.107235_bib0093","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2127273","article-title":"Is ferroptosis immunogenic? The devil is in the details!","volume":"11","author":"Kepp","year":"2022","journal-title":"Oncoimmunology"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247826001094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247826001094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T19:31:59Z","timestamp":1789932719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247826001094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":93,"alternative-id":["S0165247826001094"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2026.107235","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Killing to cure: harnessing poxvirus-driven cell death for viral immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2026.107235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Immunological Societies.","name":"copyright","label":"Copyright"}],"article-number":"107235"}}